Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance Jason Campagna, MD, PhD, joins Inventiva as President of R&D and Chief Medical Officer, succeeding Pierre Broqua, PhD, and Michael Cooreman, MDMartine Zimmermann, PharmD, joins as Executive Vice President of Regulatory Affairs and Quality AssuranceThese key leadership appointments underscore Inventiva’s commitment to long-term growth and operational excellence, with topline results from NATiV3 on track for the second half...
Inventiva annonce la nomination de Jason Campagna en tant que Président de la R&D et Directeur Médical et de Martine Zimmermann en tant que Vice-Présidente Exécutive en charge des affaires réglementaires et de l’assurance qualité Jason Campagna, MD, PhD, rejoint Inventiva en tant que Président de la R&D et Directeur Médical, succédant à Pierre Broqua, PhD, et Michael Cooreman, MDMartine Zimmermann, PharmD, rejoint l'entreprise en tant que Vice-Présidente Exécutive en charge des affaires réglementaires et de l’assurance qualité Ces nominations clés au sein de l’équipe de direction reflètent ...
Inventiva has received a $ 10m milestone payment from Chia Tai-Tianqing Pharma (CTTQ), under their 2022 licensing deal to develop and commercialize lanifibranor for MASH in Greater China. This payment follows the successful settlement of Inventiva's second financing tranche and aligns with expectations shared in their 1Q25 update. Together with the €68m cash position at 1Q25 and € ~109m net proceeds from the second tranche, Inventiva is expected to be funded through 3Q26. The Phase 3 NATiV3 tria...
Inventiva receives $10 million milestone payment from CTTQ Daix (France), New York City (New York, United States), July 7, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the receipt of a $10 million milestone payment from Chia Tai-Tianqing Pharmaceutical Group Co., Ltd (“CTTQ”), a subsidiary of Sino Biopharm. This milestone payment follows the successful settlement of the sec...
Inventiva receives $10 million milestone payment from CTTQ Daix (France), New York City (New York, United States), July 7, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the receipt of a $10 million milestone payment from Chia Tai-Tianqing Pharmaceutical Group Co., Ltd (“CTTQ”), a subsidiary of Sino Biopharm. This milestone payment follows the successful settlement of the sec...
Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease Analysis of liver sinusoidal endothelial cells (“LSEC”) from screening and end of treatment biopsies in the Phase 2b NATIVE study showed evidence of LSEC capillarization in patients without MASH, and a further increased capillarization in patients with MASH In addition, in the subgroup of patients without MASH, there was higher LSEC capillarization in patients with MASLD than thos...
Inventiva annonce la publication dans le Journal of Hepatology Reports des résultats du lanifibranor sur les cellules endothéliales sinusoïdales hépatiques chez des patients MASLD/MASH et dans des modèles précliniques de la maladie L'analyse des cellules endothéliales sinusoïdales hépatiques (« LSEC ») dans les biopsies de screening et de fin de traitement dans l'étude de Phase 2b NATIVE a mis en évidence une capillarisation des LSEC chez les patients atteints de MASLD, avec une capillarisation encore plus marquée chez les patients atteints de MASH. De plus, parmi les patients sans MASH, ...
Feedback of the companies present at the ODDO BHF Nextcap Forum Company Country Market cap. (m) Company Country Market cap. (m) Accsys Technologies € 124 Hoffmann Green € 62 Afyren € 72 Hornbach € 1 451 Altri € 1 058 IDI € 537 AMG € 550 Implenia CHF 973 AmRest PLN 3 544 Jacquet Metals € 494 Arcure € 29 Kloeckner & Co € 653 Arverne 194 Knaustabbert € 144 Austriacard Holdings € 188 Lna Santé € 270 Bastide € 218 Medincell € 398 Befesa € 1 116 Nacon € 63 CAF € 1 649 N...
Our 14th edition of the ODDO BHF Nextcap Forum took place on 11 June in Paris, and on 12 June virtually. 96 companies and 170 investors were present for more than 700 meetings organized. Overall, we noted a still cautious tone from companies, with limited visibility on a solid rebound in a persistently uncertain market environment (geopolitical situation, US politics, etc.), even if there are some signs of recovery and certain sectors remain very well positioned (leisure, energy, defence). At th...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.